Skip to main content
TrimSoMoEverything GLP-1, in one place
← All medications

FDA-approved medication

Wegovy (semaglutide)

Key facts

Last reviewed: 2026-11-04
  • •FDA label says "WEGOVY (semaglutide) injection, for subcutaneous use".
  • •FDA label says "Administer WEGOVY injection once weekly as an adjunct to diet and increased physical activity, on the same day each week, at any time of day, with or without meals."
  • •FDA label says "Inject subcutaneously in the abdomen, thigh, or upper arm."
  • •FDA label says "WEGOVY injection is indicated in combination with a reduced calorie diet and increased physical activity: • to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight. ( 1 ) • to reduce excess body weight and maintain weight reduction long term in: o adults and pediatric patients aged 12 years and older with obesity. ( 1 ) o adults with overweight in the presence of at least one weight-related comorbid condition. ( 1 ) • for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults."

FDA-approved to reduce excess body weight and maintain weight reduction long term. Read the dose schedule and safety information, and check the official prescribing information. Confirm costs and coverage with your pharmacy, insurer, or the manufacturer.

semaglutide · prefilled, single-dose pen · once weekly, subcutaneous

Active ingredient
semaglutide
Dosage form (label)
Injection: prefilled, single-dose pen
Schedule (label)
Once weekly, subcutaneous
Strengths (label)
Wegovy injection is supplied as 0.25, 0.5, 1, 1.7 and 2.4 mg single-dose pens or syringes and, as Wegovy HD, a 7.2 mg pen. Your prescriber chooses the dose; see the current prescribing information.FDA announcement, March 19, 2026 · Wegovy prescribing information (DailyMed). Accessed November 4, 2026.
Manufacturer
Novo Nordisk A/S (per label)

Brand names are trademarks of their respective owners; this site is not affiliated with them.

Abstract illustration of a soft molecule shape above a weekly calendar grid

FDA label

Wegovy dose steps (FDA label)

  1. 0.25 mg
    Weeks 1–4
    Starting dose
  2. 0.5 mg
    Weeks 5–8
    Dose step
  3. 1 mg
    Weeks 9–12
    Dose step
  4. 1.7 mg
    Weeks 13–16
    Dose step
  5. 2.4 mg
    Week 17 onward
    Label maintenance dose
Per FDA label. Your prescriber sets your dose. The label lists 1.7 mg or 2.4 mg (recommended) once weekly as the maintenance dosage for weight reduction in adults. For patients who tolerate 2.4 mg for at least 4 weeks, when additional weight reduction is clinically indicated, the label allows a maximum of 7.2 mg once weekly (Wegovy HD). Dosage is chosen by your prescriber.

FDA label answers

Common questions about Wegovy

All answers are taken directly from the official FDA prescribing information (FDA Prescribing Information (DailyMed setid ee06186f-2aa3-4990-a760-757579d8f77b, SPL version 19, revised 06/2026)).

Who is Wegovy injection approved for?

FDA label says "WEGOVY injection is indicated in combination with a reduced calorie diet and increased physical activity: • to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight. ( 1 ) • to reduce excess body weight and maintain weight reduction long term in: o adults and pediatric patients aged 12 years and older with obesity. ( 1 ) o adults with overweight in the presence of at least one weight-related comorbid condition. ( 1 ) • for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults."

How often is Wegovy injection taken?

FDA label says "Administer WEGOVY injection once weekly as an adjunct to diet and increased physical activity, on the same day each week, at any time of day, with or without meals."

What are the most common side effects listed on the label for Wegovy injection?

FDA label says "Most common adverse reactions (incidence ≥5%) in adults or pediatric patients aged 12 years and older are: nausea, diarrhea, vomiting, constipation, abdominal pain, dysesthesia, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and hair loss."

Is there a boxed warning on the Wegovy label?

Yes. FDA label says "WARNING: RISK OF THYROID C-CELL TUMORS" — "In rodents, semaglutide causes thyroid C-cell tumors at clinically relevant exposures."

What is the recommended dose escalation schedule for Wegovy injection?

FDA label says "Initiate at 0.25 mg once weekly for 4 weeks. Then follow the dosage escalation schedule in Table 1, titrating every 4 weeks to achieve the maintenance dosage."

Patient Consultation & Copay Protocol

Next Steps: Evaluating Wegovy for Your Care Plan

Transition from drug facts to clinical action. Estimate potential out-of-pocket expenses, generate consultation questions, and verify eligibility.

All Decision Tools
Copay & Savings Card

Out-of-Pocket Expense Modeling

Estimate what you might pay each month based on manufacturer assistance terms and employer benefit design.

Covered Commercial: As low as $25 / month with manufacturer card (caps apply)
Uncovered Commercial: Approx. $650 – $850 / month with manufacturer savings program
Self-Pay Option: List price assistance programs (~$1,349 list reference)
Medicare: Excluded for weight loss alone; Part D plans may cover for established CVD
Clinical Readiness

Consultation & Lab Checklist

Arrive at your appointment prepared with essential baseline bloodwork requirements and contraindication screens.

Required Bloodwork: Renal function (eGFR/creatinine), hepatic enzymes, HbA1c, and fasting lipids
Safety Screening: Screening for personal/family history of MTC, MEN 2, pancreatitis, and gallbladder disease.
Clinical Format: Includes 12 essential lab panels and formatted physician questions.
Eligibility & Providers

BMI Qualification & Directory

Verify your body mass index against official FDA prescribing label requirements and locate qualified clinicians.

FDA Label Threshold: BMI ≥30 kg/m², or ≥27 kg/m² with comorbidity; pediatric indication for ages 12+

Editorial & Regulatory Standard: TrimSoMo is an independent, non-commercial healthcare information platform. Estimated out-of-pocket costs and savings card parameters reflect publicly published 2026 manufacturer program guidelines and do not guarantee individual insurance coverage or pharmacy dispensing prices. Prescriptions require clinical evaluation by a licensed physician.

Before Starting Wegovy

Gradual Dose Titration

Per the FDA label, doses start low and increase over several months to help reduce gastrointestinal side effects. Your clinician sets your schedule. Review post-marketing data in our GLP-1 side effects from FDA labels → FAERS reports do not prove cause.

Lifestyle & Nutrition Support

In clinical studies, medication was used together with a reduced-calorie diet and increased physical activity.

Long-Term Plan

Talk with your clinician before changing or stopping treatment.

Future Pharmacotherapy Outlook

Exploring non-injectable options?

Some oral GLP-1 medicines are FDA-approved and others are still in development. The list shows each medicine's status and source.

Oral GLP-1 medicines: see which are FDA-approved and which are still in development →